Does late treatment with imatinib mesylate ameliorate radiation-induced lung fibrosis in a mouse model?
Our findings show that imatinib, even when administered after the acute inflammation has subsided, attenuates radiation-induced lung fibrosis in mice. Our data also indicate that the fibrotic fate is not only determined by the early inflammatory events but rather a complex process in which secondary events at later time points are important. Because of the clinical availability of imatinib or similar compounds, a meaningful attenuation of radiation-induced lung fibrosis in patients seems possible.
Phosphorylcholine coating does not attenuate the complement activation during CPB in neonates and infants.